J Cachexia Sarcopenia Muscle (2012) 3:149–155 35. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogo- nadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251–4. 36. Pimpinelli F, Parenti M, Guzzi F, Piva F, Hokfelt T, Maggi R. Presence of delta opioid receptors on a subset of hypothalamic gonadotropin releasing hormone (GnRH) neurons. Brain Res. 2006;1070:15–23. 37. Delitala G, Grossman A, Besser GM. The participation of hypo- thalamic dopamine in morphine-induced prolactin release in man. Clin Endocrinol (Oxf). 1983;19:437–44. 38. Mendelson JH, Ellingboe J, Judson BA, Goldstein A. Plasma testosterone and luteinizing hormone levels during levo-alpha- acetylmethadol maintenance and withdrawal. Clin Pharmacol Ther. 1984;35:545–7. 39. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84. 40. Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Larry Nicholson R, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009;117:38–43. 41. Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol. 1999;17:1493–8. 42. Palmieri G, Lotrecchiano G, Ricci G, Spiezia R, Lombardi G, Bianco AR, et al. Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol. 1996;134:431–6. 43. Stuart NS, Woodroffe CM, Grundy R, Cullen MH. Long-term toxicity of chemotherapy for testicular cancer—the cost of cure. Br J Cancer. 1990;61:479–84. 44. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9. 45. Hijazi RA, Cunningham GR. Andropause: is androgen replace- ment therapy indicated for the aging male? Annu Rev Med. 2005;56:117–37. 46. Shores MM, Sloan KL, Matsumoto AM, Moceri VM, Felker B, Kivlahan DR. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162–7. 47. Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT et al. Interaction of gonadal status with systemic in- flammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Can- cer.19:391–401. 48. Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Snowden JA, Shalet SM et al. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study. Cancer.116:1592–601. 49. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, et al. 5-year urinary and sexual outcomes after radical prosta- tectomy: results from the Prostate Cancer Outcomes Study. J Urol. 2008;179:S40–4. 155 50. Deliveliotis C, Liakouras C, Delis A, Skolarikos A, Varkarakis J, Protogerou V. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age- matched control population. Urol Res. 2004;32:283–9. 51. Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010;39:1016–24. 52. Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, et al. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys. 2009;74:1143–9. 53. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–42. 54. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20:378–87. 55. Jockenhovel F, Minnemann T, Schubert M, Freude S, Hubler D, Schumann C, et al. Comparison of long-acting testosterone undeca- noate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men. Eur J Endocrinol. 2009;160:815–9. 56. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085–98. 57. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual func- tion. J Clin Endocrinol Metab. 2003;88:2673–81. 58. Rabkin JG, Rabkin R, Wagner G. Testosterone replacement thera- py in HIV illness. Gen Hosp Psychiatry. 1995;17:37–42. 59. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV- associated weight loss. AIDS. 1997;11:1347–52. 60. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999;340:1740–50. 61. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17:3299–306. 62. Evans WJ, Smith M, Morley JE, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly sub- jects: implications for cancer cachexia patients. J Clin Oncol. 2007;25:522S. 63. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.